National Healthcare financials
$224.16−0.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.52B | $1.31B | $1.14B | $1.09B | $1.07B | $1.03B | $996.4M | $980.3M | $963.9M | $923.6M |
| Gross profit | $1.52B | $1.31B | $1.14B | $1.09B | $1.07B | $1.03B | $996.4M | $980.3M | $963.9M | $923.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $128.4M | $89.9M | $57.5M | $28.7M | $51.8M | $51.3M | $54.1M | $60.8M | $59.0M | $64.5M |
| Net income | $120.0M | $101.9M | $66.8M | $22.4M | $138.6M | $41.9M | $68.2M | $59.0M | $56.2M | $50.5M |
| Net margin | 7.9% | 7.8% | 5.9% | 2.1% | 12.9% | 4.1% | 6.8% | 6.0% | 5.8% | 5.5% |
| Diluted EPS | $7.67 | $6.53 | $4.34 | $1.45 | $8.99 | $2.72 | $4.44 | $3.87 | $3.69 | $3.32 |
| EBITDA | $173.3M | $131.9M | $99.5M | $69.2M | $100.7M | $91.6M | $94.6M | $102.7M | $101.7M | $103.5M |
| Operating cash flow | $185.1M | $107.3M | $111.2M | $8.7M | $62.4M | $203.3M | $101.5M | $100.0M | $98.7M | $92.5M |
| Free cash flow | $148.6M | $79.7M | $83.3M | -$21.5M | $23.0M | $181.4M | $75.1M | $70.2M | $66.4M | $29.9M |
| Diluted shares | 15.6M | 15.6M | 15.4M | 15.4M | 15.4M | 15.4M | 15.4M | 15.2M | 15.2M | 15.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $92.8M | $76.1M | $107.1M | $58.7M | $107.6M | $147.1M |
| Short-term investments | $163.0M | $174.8M | $156.1M | $162.5M | $196.1M | $197.6M |
| Total debt | $40.0M | $137.0M | $860.0K | $34.9M | $10.5M | $15.0M |
| Total assets | $1.53B | $1.52B | $1.31B | $1.28B | $1.40B | $1.36B |
| Total liabilities | $451.9M | $541.3M | $400.3M | $397.9M | $494.9M | $563.9M |
| Shareholders' equity | $1.07B | $983.2M | $910.5M | $877.5M | $908.5M | $798.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology